← Back to patent-cliff list
坎地沙坦西酯
Tier C — Watch / tradeCandesartan Cilexetil
阿斯利康
Originator
1997
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：AT1
Brand：Kenzen、Ratacand、Blopress、Tiadyl、Amias、Racanda、必洛斯、Atacand、Parapres
Indications (approved)：高血压、心脏衰竭、原发性高血压
Regional status
US
批准上市
1998-06-04
EU
批准上市
1997-04-29
China
批准上市
2003-08-05
Japan
批准上市
1999-03-12
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Candesartan Cilexetil?
Approved indications include: 高血压, 心脏衰竭, 原发性高血压.
When does the Candesartan Cilexetil patent expire?
No public expiry year is available for Candesartan Cilexetil yet; this page updates once verified.
How do I get a quote for Candesartan Cilexetil intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25